AI assistant
Denali Therapeutics Inc. — Director's Dealing 2021
Jan 7, 2021
31637_dirs_2021-01-06_a9c72971-52b1-4407-b8af-9186961084fc.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-01-04
Reporting Person: Ho Carole (Chief Medical Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-01-04 | Restricted Stock Units | $ | A | 30000 | Acquired | Common Stock (30000) | Direct | |
| 2021-01-04 | Stock Option (right to buy) | $70.86 | A | 90000 | Acquired | 2031-01-03 | Common Stock (90000) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F2: 25% of the restricted stock units shall vest on January 4, 2022 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.
F3: 25% of the shares subject to the option shall vest on January 4, 2022, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.